Display options
Cite
Lazzeroni M, Macis D, Decensi A, et al. The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trial. Ecancermedicalscience. 2008;2:67doi: 10.3332/ecancer.2008.67.
Lazzeroni, M., Macis, D., Decensi, A., Gandini, S., Sandri, M. T., Serrano, D., Guerrieri-Gonzaga, A., Johansson, H., Mora, S., Daldoss, C., Omodei, U., & Bonanni, B. (2008). The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trial. Ecancermedicalscience, 267. https://doi.org/10.3332/ecancer.2008.67
Lazzeroni, M, et al. "The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trial." Ecancermedicalscience vol. 2 (2008): 67. doi: https://doi.org/10.3332/ecancer.2008.67
Lazzeroni M, Macis D, Decensi A, Gandini S, Sandri MT, Serrano D, Guerrieri-Gonzaga A, Johansson H, Mora S, Daldoss C, Omodei U, Bonanni B. The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trial. Ecancermedicalscience. 2008;2:67. doi: 10.3332/ecancer.2008.67. Epub 2008 Feb 06. PMID: 22275964; PMCID: PMC3234057.
Copy Download .nbib Format: NLM
Share it on

Ecancermedicalscience. 2008;2:67. doi: 10.3332/ecancer.2008.67. Epub 2008 Feb 06.

The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trial.

Ecancermedicalscience

M Lazzeroni, D Macis, A Decensi, S Gandini, M T Sandri, D Serrano, A Guerrieri-Gonzaga, H Johansson, S Mora, C Daldoss, U Omodei, B Bonanni

Affiliations

  1. Cancer Prevention and Genetics, European Institute of Oncology, 20141 Milan, Italy.

PMID: 22275964 PMCID: PMC3234057 DOI: 10.3332/ecancer.2008.67

Abstract

BACKGROUND: We have previously reported the favourable effect of transdermal estradiol (E2), relative to oral conjugated equine oestrogen (CEE), on ultrasensitive C-reactive protein after 12 months of treatment in a retinoid-placebo controlled two-by-two randomized breast cancer prevention trial (Decensi A et al (2002) Circulation106 10 1224-8). Here, we investigate the changes in lipids and clotting profile in patients of the same trial.

METHODS AND RESULTS: Recent post-menopausal women were randomised to either oral CEE 0.625 mg/day and placebo (n = 55), CEE and fenretinide 200 mg/day (n = 56), transdermal E2 50 mg/day and placebo (n = 59) or E2 and fenretinide 200 mg/day (n = 56). Sequential medroxyprogesterone acetate 10 mg/day was given in each group. After 12 months, there was a statistically significant effect of the route of administration of hormone replacement therapy (HRT) on fibrinogen levels; the median percentage change being -5.7% with CEE and -1.1% with E2 (p = 0.012). Total cholesterol decreased in all arms (p < 0.0001). HDL-C decreased significantly with transdermal E2 (p = 0.006) compared to oral CEE and with fenretinide relative to placebo (p<0.001). Triglycerides exhibited an opposite modulation in the HRT route, with a 21.4% median increase with oral CEE and an 8.6% reduction with transdermal E2 (p < 0.0001). Antithrombin-III showed a 4% borderline significant reduction in the fenretinide arm relative to placebo, irrespective of the HRT administration route (p = 0.055).

CONCLUSIONS: Our data indicate that transdermal E2 may be preferable to oral CEE based on its safer cardiovascular risk profile. Fenretinide modified some cardiovascular risk biomarkers and confirmed a safer profile compared to other retinoids.

References

  1. Ann Intern Med. 1978 Aug;89(2):157-61 - PubMed
  2. Fertil Steril. 2001 Jul;76(1):13-24 - PubMed
  3. J Clin Oncol. 2001 Mar 15;19(6):1664-70 - PubMed
  4. JAMA. 1998 Aug 19;280(7):605-13 - PubMed
  5. Int J Cardiol. 2003 Jun;89(2-3):257-65 - PubMed
  6. Chest. 2002 Mar;121(3):906-20 - PubMed
  7. Cancer Lett. 1996 Oct 1;107(1):65-71 - PubMed
  8. N Engl J Med. 1997 Mar 6;336(10):683-90 - PubMed
  9. Eur J Clin Nutr. 2005 Oct;59(10):1173-80 - PubMed
  10. J Clin Endocrinol Metab. 2001 Mar;86(3):1140-3 - PubMed
  11. J Clin Endocrinol Metab. 2003 Mar;88(3):1303-9 - PubMed
  12. JAMA. 2002 Jul 17;288(3):321-33 - PubMed
  13. Clin Cancer Res. 2004 Jul 1;10(13):4389-97 - PubMed
  14. N Engl J Med. 1993 Apr 29;328(17):1220-5 - PubMed
  15. Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):3071-8 - PubMed
  16. Thromb Haemost. 1992 Oct 5;68(4):392-5 - PubMed
  17. Arterioscler Thromb Vasc Biol. 1999 Apr;19(4):893-9 - PubMed
  18. JAMA. 2002 Aug 28;288(8):980-7 - PubMed
  19. Treat Endocrinol. 2004;3(2):105-15 - PubMed
  20. Breast Cancer Res Treat. 1999 Oct;57(3):277-83 - PubMed
  21. Lancet. 1990 Mar 31;335(8692):765-74 - PubMed
  22. Clin Chem. 1972 Jun;18(6):499-502 - PubMed
  23. Circulation. 2002 Sep 3;106(10):1224-8 - PubMed
  24. Cancer Res. 1996 Mar 1;56(5):1056-62 - PubMed
  25. Lancet. 1999 Aug 7;354(9177):487-8 - PubMed
  26. Am Heart J. 1997 Oct;134(4):764-71 - PubMed
  27. J Intern Med. 2001 Mar;249(3):237-46 - PubMed
  28. J Cardiovasc Risk. 1996 Apr;3(2):213-9 - PubMed
  29. J Clin Endocrinol Metab. 1997 Dec;82(12):3952-4 - PubMed
  30. Thromb Haemost. 2001 Aug;86(2):550-6 - PubMed
  31. Thromb Res. 1997 Feb 1;85(3):185-93 - PubMed
  32. Am J Obstet Gynecol. 2003 Nov;189(5):1221-7 - PubMed
  33. N Engl J Med. 1996 Aug 15;335(7):453-61 - PubMed
  34. Eur Heart J. 1998 Oct;19 Suppl M:M8-14 - PubMed
  35. Br J Obstet Gynaecol. 1997 Nov;104 Suppl 16:32-7 - PubMed
  36. Atherosclerosis. 1998 Jun;138(2):229-35 - PubMed
  37. Circulation. 2004 Oct 26;110(17):2678-86 - PubMed
  38. Int J Fertil Menopausal Stud. 1993;38 Suppl 1:30-5 - PubMed
  39. Circulation. 2003 Aug 19;108(7):808-13 - PubMed
  40. Prev Med. 1991 Jan;20(1):47-63 - PubMed
  41. Tumour Biol. 1997;18(1):22-9 - PubMed
  42. J Thromb Haemost. 2003 Sep;1(9):1984-91 - PubMed
  43. Ann Oncol. 2006 Jul;17(7):1065-71 - PubMed
  44. Nature. 1993 Apr 29;362(6423):801-9 - PubMed
  45. J Cardiovasc Pharmacol. 2006 Apr;47(4):542-8 - PubMed
  46. Atherosclerosis. 2003 May;168(1):123-9 - PubMed

Publication Types